Avilex Pharma ApS, of Copenhagen, Denmark, said it has received seed funding from Novo Seeds, the early stage financing arm of Novo A/S, which will be used to support the development of dimeric ligands targeting PDZ domains...In other news, GSK experienced manufacturing delays for manufacture and supply of Horizant (gabapentin enacarbil), partnered with XenoPort Inc., of Santa Clara, Calif., resulting in a stockout of the drug...The firms will aim to offer pharma and biotech companies a set of fully

letrozole alone as a first-line treatment in postmenopausal patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer

Eddingpharm, of Hong Kong, entered a collaboration with GlaxoSmithKline plc (GSK), of London, whereby Eddingpharm will acquire from GSK the exclusive right in mainland China to import, market, promote, distribute and sell Tykerb (lapitinib), a treatment for advanced or metastatic breast cancer that was recently approved by the China State Food and Drug Administration...The firms will aim to offer pharma and biotech companies a set of fully integrated nuclear receptor drug discovery capabilities by

patients with advanced or metastatic solid tumors whose disease is no longer responsive to available treatments...In other news, GSK recently agreed to a nonexclusive material transfer, patent and know-how license deal with the Health Protection Agency (HPA) for the development and manufacture of a next-generation polio vaccine

The restricted stock units vest over three years, and each is subject to terms of the company's 2012 equity incentive plan...Seattle Genetics Inc., of Bothell, Wash., reported that Health Canada has approved for marketing Adcetris (brentuximab vedotin), to treat: Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least two multi-agent chemotherapy regimens in patients who are not ASCT candidates...Valeant Pharmaceuticals International Inc., of Montreal

Astellas Pharma Inc., of Tokyo, said the FDA accepted for filing a supplemental new drug application for Tarceva (erlotinib) for first-line use in patients with locally advanced or metastatic non-small-cell lung cancer whose tumors have epidermal growth factor receptor (EGFR)-activating mutations...In other news, Boehringer Ingelheim said it enrolled the first patients in its Phase III interferon-free (IFN-free) program, HCVerso, testing its IFN-free polymodal regimen combining faldaprevir (BI

Astellas Pharma Inc., of Tokyo, said the FDA accepted for filing a supplemental new drug application for Tarceva (erlotinib) for first-line use in patients with locally advanced or metastatic non-small-cell lung cancer whose tumors have epidermal growth factor receptor (EGFR)-activating mutations

Afatinib is under review for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer with an epidermal growth factor receptor mutation as detected by an FDA-approved test

Distribution of Prothena ordinary shares in the demerger is conditioned upon, among other conditions to the demerger, a registration statement filed with the SEC, having been declared effective by the SEC and the affirmative vote of the Elan shareholders...Galderma Pharma SA, of Lausanne, Switzerland, and Valeant Pharmaceuticals International Inc., of Montreal, reached agreement on terms of a revised North American aesthetics arrangement, resolving Galderma's pending litigation related to Valeant's

Reddy's Laboratories Ltd., of Hyderabad, India, acquired exclusive marketing and sales rights to Pamorelin LA (triptorelin) Depot, by Debiopharm Group, of Lausanne, Switzerland, in India for locally advanced or metastatic, hormone-dependent prostate cancer

The news came late Thursday, shortly after the company disclosed FDA approval of Cometriq in MTC...Isotechnika Pharma Inc., of Edmonton, Alberta, said a partial award has been issued in the company's ICC arbitration regarding its right to terminate the development, distribution and license agreement with Iljin Life Sciences Co

Those and other data are set to be presented at the American Society for Hematology meeting in Atlanta next month...was granted regulatory clearance from authorities in Thailand to advance lead AlloStim immunotherapy to the Phase II/III stage in advanced metastatic breast cancer...Under the terms, Nordic Pharma will commercialize the product in those areas, with Medigene receiving milestone payments and double-digit royalties on sales, as well as certain payments related to the manufacture and supply

Astellas Pharma Inc., of Tokyo, said it submitted a supplemental new drug application seeking approval of Tarceva (erlotinib) in first-line treatment of patients with locally advanced or metastatic non-small-cell lung cancer whose tumors have EGFR-activating mutations as detected by an approved test

Astellas Pharma Inc., of Tokyo, said it submitted a supplemental new drug application seeking approval of Tarceva (erlotinib) in first-line treatment of patients with locally advanced or metastatic non-small-cell lung cancer whose tumors have EGFR-activating mutations as detected by an approved test

Bristol-Myers Squibb Co., of New York, said the National Institute of Health and Clinical Excellence decided to recommend Yervoy (ipilimumab), which is approved in Europe for treating advanced metastatic melanoma, within the final appraisal determination...That decision will enable eligible patients in England and Wales to routinely access treatment with Yervoy through the National Health Services

In other news, Cellectis said it signed two exclusive license agreements with Iowa State University granting the firm worldwide rights to inventions related to TAL effector-nucleases (TALENs) and monomeric TALENs...Pharma Two B Ltd., of Rehovot, Israel, completed a second round of financing for $8 million to develop its fixed-dose-combination product, P2B001, for Parkinson's disease and to complete a Phase IIb trial

BioAlliance Pharma SA, of Paris, said it signed a deal with Shafayab Gostar to distribute Loramyc (miconazole Lauriad mucoadhesive buccal tablet) in Iran for the treatment of oropharygeal candidiasis in immunocompromised patients...for turoctocog alfa, a third-generation recombinant coagulation Factor VIII intended for prevention and treatment of bleeding with people with hemophilia A. In other news, Novo Nordisk said the European Committee for Medicinal Products for Human Use adopted a positive

Eli Lilly and Co., of Indianapolis, said the FDA approved the label inclusion for Alimta (pemetrexed) with Phase III data demonstrating progression-free survival and overall survival advantages in the continuation maintenance setting for patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer following first-line Alimta plus cisplatin

Patients were randomized to three dose groups of intravenously administered ALX-0061 (1mg/kg every 4 weeks, 3mg/kg every 4 weeks and 6mg/kg every 8 weeks) or to placebo...LEO Pharma A/S, of Ballerup, Denmark, disclosed plans to establish five long-term, strategic research collaborations in Australia, France, Germany and the U.S